Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ali Mirhosseini

Cardiovascular Disease Tracy, CA Medical Doctor

NPI 1831485705 CMS profile 1380438

1530 Bessie Ave Ste 101, Tracy, CA 95376

Open in the dashboard

General payments

$8,629

387 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ali Mirhosseini of Tracy, CA is reported in the CMS Open Payments database as having received $8,629 across 387 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,345 100
2024 General $1,343 56
2023 General $1,325 49
2022 General $1,792 93
2021 General $1,285 65
2020 General $464 21
2019 General $75 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ali Mirhosseini
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Ali Mirhosseini were reported at $2,345. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Ali Mirhosseini Cardiovascular Disease median Middle half National median
2019 $75 $450 $127–$1,392 $163
2020 $464 $242 $77–$751 $114
2021 $1,285 $335 $101–$1,037 $132
2022 $1,792 $395 $121–$1,211 $149
2023 $1,325 $443 $136–$1,283 $160
2024 $1,343 $450 $136–$1,323 $164
2025 $2,345 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $901 41 payments
  2. Janssen Pharmaceuticals, Inc $751 53 payments
  3. AstraZeneca Pharmaceuticals LP $725 20 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $696 38 payments
  5. Amgen Inc. $542 31 payments
  6. Novartis Pharmaceuticals Corporation $493 28 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $488 29 payments
  8. E.R. Squibb & Sons, L.L.C. $444 21 payments
  9. Pfizer Inc. $424 19 payments
  10. Atricure, Inc. $404 7 payments
  11. Other $2,761 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,352 380 payments
  2. Education $277 7 payments
Products named General payments · program years 2019–2025
  1. VERQUVO $1,005 47 payments
  2. XARELTO $751 53 payments
  3. Kerendia $521 33 payments
  4. JARDIANCE $381 24 payments
  5. ATRICLIP LAA EXCLUSION SYSTEM $352 6 payments
  6. Repatha $322 18 payments
  7. ELIQUIS $291 12 payments
  8. FARXIGA $288 13 payments
  9. LEQVIO $277 15 payments
  10. CAMZYOS $271 10 payments
  11. Other $5,210 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

4,306

Median for Cardiology: 2,533

Drug cost

$1,255,063

Median for Cardiology: $485,213

Branded share of claims

31.4%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 229 $275,474
Eliquis Apixaban Brand 238 $264,160
Xarelto Rivaroxaban Brand 115 $143,844
Ozempic Semaglutide Brand 68 $95,144
Farxiga Dapagliflozin Propanediol Brand 87 $94,342
Rybelsus Semaglutide Brand 34 $74,435
Entresto Sacubitril/Valsartan Brand 61 $72,375
Multaq Dronedarone Hcl Brand 66 $51,561
Repatha Sureclick Evolocumab Brand 40 $46,218
Vascepa Icosapent Ethyl Brand 51 $33,803

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 60 billing codes

Paid by Medicare

$578,357

Of which drugs: $12,507

Medicare patients

1,390

Average age 76

Services billed

8,089

720 women, 670 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 66%
Diabetes 52%
Arthritis 46%
Chronic kidney disease 45%
Heart failure 40%
Atrial fibrillation 34%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 63 252 $1,460
Injection, aminophyllin, up to 250 mg J0280 Office 31 31 $205

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $151
$151 — —
VERQUVO
  • Merck Sharp & Dohme Corporation $139
$139 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $98
$98 20 —
ELIQUIS
  • PFIZER INC. $57
  • E.R. Squibb & Sons, L.L.C. $38
$94 238 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $89
$89 87 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

387 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record